Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Bellicum Pharmaceuticals Inc (BLCM)

Bellicum Pharmaceuticals Inc (BLCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Fri Jul 1, 2022

HOUSTON, July 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular...

BLCM : 0.0748 (-6.62%)
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire - Mon May 2, 2022

HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular...

BLCM : 0.0748 (-6.62%)
Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update Globe Newswire - Thu Mar 24, 2022

- Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2...

BLCM : 0.0748 (-6.62%)
Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference Globe Newswire - Wed Jan 26, 2022

HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular...

BLCM : 0.0748 (-6.62%)
Bellicum Regains Compliance with Nasdaq Continued Listing Requirements Globe Newswire - Mon Dec 13, 2021

HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular...

BLCM : 0.0748 (-6.62%)
Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update Globe Newswire - Thu Nov 4, 2021

- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - -...

BLCM : 0.0748 (-6.62%)
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Globe NewsWire - Fri Sep 3, 2021

HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair,...

BLCM : 0.0748 (-6.62%)
Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch Globe NewsWire - Wed Sep 1, 2021

HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc . (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas...

BLCM : 0.0748 (-6.62%)
Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update Globe NewsWire - Thu Aug 12, 2021

- Entered into a licensing agreement with two leading oncology research and treatment centers for use of CaspaCIDe ® safety switch technology -

BLCM : 0.0748 (-6.62%)
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe NewsWire - Mon Jul 26, 2021

HOUSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced an equity inducement...

BLCM : 0.0748 (-6.62%)

Barchart Exclusives

Tesla Stock Forecast Post-Q2 Earnings: 'Present Imperfect, Future Uncertain' Barchart - 21 minutes ago
Tesla stock crashed following its Q2 earnings earlier this week. Here are the key takeaways from the report, and the forecast for the company amid a challenging macro environment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot